Who Paid My Doc
Philip Barger
Adult Congenital Heart Disease Cleveland, OH Medical Doctor
NPI 1407936826 CMS profile 830460
2101 Adelbert Rd, Cleveland, OH 44106
General payments
$99
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Philip Barger of Cleveland, OH is reported in the CMS Open Payments database as having received $99 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $99 | 1 |
Beside peers
- Philip Barger
- Adult Congenital Heart Disease median
- Middle half of Adult Congenital Heart Disease
- National median
In program year 2025, general payments to Philip Barger were reported at $0. Among 56 Adult Congenital Heart Disease profiles paid that year, the median was $272 and the middle half received between $51 and $642.
Show as a table
| Year | Philip Barger | Adult Congenital Heart Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $202 | $71–$498 | $163 |
| 2020 | $0 | $127 | $28–$236 | $114 |
| 2021 | $0 | $138 | $34–$310 | $132 |
| 2022 | $0 | $275 | $125–$1,572 | $149 |
| 2023 | $99 | $215 | $58–$1,454 | $160 |
| 2024 | $0 | $273 | $84–$801 | $164 |
| 2025 | $0 | $272 | $51–$642 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 9 drugsPart D claims
245
Drug cost
$27,627
Branded share of claims
18.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | Brand | 45 | $25,836 | |
| Warfarin Sodium | Generic | 23 | $607 | |
| Metoprolol Succinate | Generic | 31 | $413 | |
| Spironolactone | Generic | 28 | $217 | |
| Furosemide | Generic | 51 | $208 | |
| Bumetanide | Generic | 17 | $139 | |
| Losartan Potassium | Generic | 11 | $121 | |
| Lisinopril | Generic | 21 | $60 | |
| Amlodipine Besylate | Generic | 18 | $27 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 15 billing codesPaid by Medicare
$2,375
Medicare patients
30
Services billed
59
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 47% | |
| Heart failure | 43% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Adult Congenital Heart Disease in Ohio
Saurabh Rajpal
Adult Congenital Heart Disease · Columbus, OH
Curtis Daniels
Adult Congenital Heart Disease · Columbus, OH
William Kay
Adult Congenital Heart Disease · Fairfield, OH
Alexander Opotowsky
Adult Congenital Heart Disease · Cincinnati, OH
Clayton Smith
Adult Congenital Heart Disease · Cincinnati, OH
Hassan Almeneisi
Adult Congenital Heart Disease · Cincinnati, OH
Related records
Adult Congenital Heart Disease in Ohio
Practitioners in the same specialty and state, ranked by reported value.
All Adult Congenital Heart Disease
Everyone recorded under this specialty, nationwide.
Doctors in Ohio
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.